Navigation Links
TriReme Announces Signing of a Master Distribution Agreement in China
Date:3/26/2013

PLEASANTON, Calif. and SINGAPORE, March 26, 2013 /PRNewswire/ -- TriReme Medical, Inc. and its affiliates (TriReme) announced today that it has signed a comprehensive agreement with Weihai Weigao Medical Devices, Ltd for the distribution of its products in the People's Republic of China. Weigao will act as TriReme's master distributor by selling TriReme products directly to hospitals as well as connecting TriReme products into its vast nationwide distribution network. This agreement complements TriReme's strategy of focusing on Asia, the fastest growing market in interventional cardiology.

"Due to many factors including increased affordability, aging population and an increase in the number of state-of-the-art medical facilities, China has become the world's second largest market in terms of the volume of interventional coronary vascular procedures," stated Eitan Konstantino Ph.D, CEO and President of TriReme. "For similar reasons, we expect that the number of peripheral vascular procedures will rise dramatically in the coming years to the point where China becomes the world's largest market in terms of total vascular interventions."

Ms CHU Swee Yeok, CEO and President, EDBI and Bio*One Capital said: "We are confident that TriReme products and technologies will lead to better clinical outcomes for Chinese patients and are thrilled to partner with a distinguished player like Weigao to introduce TriReme products into the world's fastest growing healthcare market. Such a partnership is a great example of how highly innovative companies like TriReme can leverage on Singapore as a base to access vital Asia markets for their growth."

"Weigao remains committed to partnering with healthcare providers
'/>"/>

SOURCE TriReme Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TriReme Announces a New Round of Financing Totalling US$18 Million
2. TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter
3. Genalyte Announces CE Mark For Maverick(TM) Detection System And Signs On First European Distributors
4. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
5. ECRI Institute Announces 2013 Health Devices Achievement Award -- Call for Entries
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
7. Research and Markets Announces The Release of Neuromodulation Market - Forecasts to 2017
8. SARcode Bioscience Announces Acquisition by Shire US Holdings Inc.
9. Creative Edge Nutrition, Inc. Announces the Entrance into the Medical Marijuana Sector
10. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
11. United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Medimetriks Pharmaceuticals, Inc. announced ... Phase III clinical study for Ozenoxacin, a novel ... owns the exclusive U.S. rights to Ozenoxacin 1% ... at 44 centers with an emphasis on U.S. ... 2 months and older with a clinical diagnosis ...
(Date:7/30/2015)... SAN FRANCISCO , July 30, 2015 ... devices market is expected to reach USD 23.01 ... Grand View Research, Inc. Growing base of geriatric population, ... and infections, and rising level of awareness among target ... impact rendering drivers over the forecast period. According to ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... of Iomai Adjuvant ... Patch -, ... announced that it has begun dosing in a Phase 1/2,study that will ... in combination with an injected,H5N1 influenza vaccine. The Iomai patch, which ...
... Biopure Corporation,(Nasdaq: BPUR ) today announced that it ... use protocol submitted by the company in July. At,the ... for a Phase,2 randomized trial for the treatment of ... alloantibody anemia but,excluding sickle cell anemia. Hemopure has been ...
Cached Medicine Technology:Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 2Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 3Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 4Biopure Reports on Meeting with the FDA 2Biopure Reports on Meeting with the FDA 3
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, industry-leading provider of ... magazine, its multimedia publication focused on implant dentistry, is now available in print ... 6, Issue 2, as well as past issues of the dental laboratory’s quarterly ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students ... World Games, the largest sports and humanitarian event in the world this year and ... World Games, held July 25 through August 2, 2015, benefited from the participation of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... On July 23rd ... billion in taxpayer money to fund the state’s large prison system, which has amassed ... the highest rates of incarceration. In light of President Obama’s recent reduction of non ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer patients ... designed specifically for the elimination of excess tissue under the chin, referred to ... state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Gummy ... including lip lowering, gum contouring and surgery, as well as the patented gum depigmentation ... that has made him popular with many patients from around the world. , “Like ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... Researchers at the Food Technology Plant Special Research Centre ... celiac disease// otherwise called as gluten sensitive enteropathy. This ... known to have enhanced nutritive value and increased shelf ... of gluten, forcing sufferers to follow a strictly gluten-free ...
... plenty of good reasons, the term “trans fat” leaves ... Typically, trans fatty acids are bad for health, but// ... have coaxed out significant health benefits by juggling the ... professor of food science, and graduate student Vishal Jain ...
... today urged Australians to spare a thought this week for ... time of year for most people means joyful gatherings with ... and despair,' Dr Yong said. ,'The social circuit, ... can cause depression for those who are socially isolated. ...
... obstinate, as scientists have discovered, as they portray a ... extremely// difficult to annihilate. In fact radiation could even ... from the University of California, Los Angeles, who are ... cells that get radiation resistant and render breast cancer ...
... producing cane sugar with lower glycaemic index (GI) that it ... ranking system for carbohydrates based on their immediate effect on ... risk of diabetes because they trigger rapid increases in blood ... ,The sugar, developed by firm 'Horizon Science of ...
... 'DNA-diets', advertised extensively on the internet, making tall claims of ... ,A study, spearheaded by researchers at the Economic and Social ... University of Exeter, is the first study of its kind ... diets are also called 'nutrigenomic' diets that are customized diet ...
Cached Medicine News:Health News:Gluten Free Bread: Boon for Celiac Disease 2Health News:Healthy Potato Chips: A Trans Fat Oil With Health Benefits 2
... implanted bone growth stimulator for the treatment ... implanted bone growth stimulator is a useful ... surgery is already planned or when patient ... OsteoGen is totally surgically implanted, patients are ...
... Stryker is proud to offer ... on the market at only ... design incorporates a superior flow ... intuitive locking mechanisms. The complementing ...
... Cryocare® CS is ... placement and treatment system ... and allow unlimited flexibility. ... to meet specific physician ...
Sterile Disposable Thermal Cautery Tips for Vasectomy. Individually peel-pouched with dual plastic sheaths to cover non-sterile handle. Box of 10 tips....
Medicine Products: